BEIJING, Dec. 14, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company has received the manufacturing license from the State Food and Drug Administration ("SFDA") for Dipyridamole Aspirin, a stroke-prevention product developed in-house. The Company expects to begin marketing this product in the second quarter of 2011 after completing its production and sales preparation process.
Baizhong Xue, the Company's Chairman and CEO, commented, "We are so pleased with our continued progress diversifying our product portfolio, which will bring us closer to our goal of becoming one of China's leading diversified biopharmaceutical companies. With Dipyridamole Aspirin, as well as with the imported cardiovascular product for which we recently acquired exclusive marketing rights in China, we expect to further expand our strong distribution capabilities beyond inpatient product channels. In fact, we already began building out a specialized sales and marketing team focused on outpatient cardiovascular products."
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, Kaitong®, a cardiocerebral and peripheral vascular product, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit for more information.
Safe-Harbor Statement
This press release contains statements of a forward-looking nature. These statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including certain plans, expectations, goals, and projections, which are subject to numerous assumptions, risks, and uncertainties. These forward-looking statements may include, but are not limited to, statements containing words such as "may," "could," "would," "plan," "anticipate," "believe," "estimate," "predict," "potential," "expects," "intends" and "future" or similar expressions. Among other things, the statements relating to the Company's expected progress on the new product portfolio may contain forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to change at any time. These forward-looking statements are based upon management's current expectations and are subject to a number of risks, uncertainties and contingencies, many of which are beyond the Company's control, that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The Company's actual results could differ materially from those contained in the forward-looking statements due to a number of factors, including those described under the heading "Risk Factors" in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F.
CONTACT: ICR, LLC In the U.S.: Ashley M. Ammon 1-646-277-1227 In China: Wen Lei Zheng: 86-10-6583-7510